These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 7097457)

  • 21. Parameter-free testing of the shape of a probability distribution.
    Broom M; Nouvellet P; Bacon JP; Waxman D
    Biosystems; 2007; 90(2):509-15. PubMed ID: 17293028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmaca Fennica and the information about parallel pharmaceutical derivatives].
    Kettunen K
    Duodecim; 2003; 119(17):1686; author reply 1687. PubMed ID: 14587451
    [No Abstract]   [Full Text] [Related]  

  • 23. Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin.
    ; ;
    Stat Med; 2006 May; 25(10):1628-38. PubMed ID: 16639773
    [No Abstract]   [Full Text] [Related]  

  • 24. [European legislation on biological similarity recommendations of the European Agency on Medications concerning drug quality].
    Prugnaud JL
    Nephrol Ther; 2009 Feb; 5 Spec No1():3-5. PubMed ID: 19233075
    [No Abstract]   [Full Text] [Related]  

  • 25. Generic vs. brand name drugs--defining and enforcing standards.
    Lasagna LC
    Internist; 1979 May; 20(4):11, 13. PubMed ID: 10316827
    [No Abstract]   [Full Text] [Related]  

  • 26. Generic drug prices fall 7%-24%; groups sort out manufacturers.
    Bernstein T
    Hosp Mater Manage; 1989 Feb; 14(2):8-10. PubMed ID: 10318186
    [No Abstract]   [Full Text] [Related]  

  • 27. Estimation of distribution algorithms with Kikuchi approximations.
    Santana R
    Evol Comput; 2005; 13(1):67-97. PubMed ID: 15901427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modelling drug dissolution from controlled release products using genetic programming.
    Do DQ; Rowe RC; York P
    Int J Pharm; 2008 Mar; 351(1-2):194-200. PubMed ID: 18053658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Framework and development of a comprehensive drug product coding system.
    DeVito CA; Aldridge GW; Wilson A; Vidis JS; Goldberg T; Dickson WM; Moore WE
    Contemp Pharm Pract; 1979; 2(2):62-5. PubMed ID: 10316818
    [No Abstract]   [Full Text] [Related]  

  • 30. New York State and drug lists: a history of confusion.
    Stetler CJ
    Med Mark Media; 1978 Sep; 13(9):36, 38, 40 passim. PubMed ID: 10316687
    [No Abstract]   [Full Text] [Related]  

  • 31. The European regulatory experience.
    Lewis JA
    Stat Med; 2002 Oct; 21(19):2931-8. PubMed ID: 12325109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality drugs and the Saskatchewan formulary.
    Johnson GE
    Can J Hosp Pharm; 1975; 28(3):84-6. PubMed ID: 10316621
    [No Abstract]   [Full Text] [Related]  

  • 33. Regulatory aspects of drug dissolution from a European perspective.
    Graffner C
    Eur J Pharm Sci; 2006 Nov; 29(3-4):288-93. PubMed ID: 16950606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel statistical-thermodynamic methods to predict protein-ligand binding positions using probability distribution functions.
    Ruvinsky AM; Kozintsev AV
    Proteins; 2006 Jan; 62(1):202-8. PubMed ID: 16287127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should evidence-based proof of efficacy as defined for a specific therapeutic agent be extrapolated to encompass a therapeutic class of agents?
    Antman EM; Ferguson JJ
    Circulation; 2003 Nov; 108(21):2604-7. PubMed ID: 14638523
    [No Abstract]   [Full Text] [Related]  

  • 36. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Interpretation mistakes in statistical methods: their importance and some recommendations].
    Monterde i Bort H; Pascual Llobel J; Frías Navarro MD
    Psicothema; 2006 Nov; 18(4):848-56. PubMed ID: 17296128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Ranking the efficacy of drugs--a question of "class"? It is difficult to determine equivalency of two different treatments].
    Liedholm H; Linné AB
    Lakartidningen; 2002 Sep; 99(36):3492-4, 3497-9, 3502. PubMed ID: 12362748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of bioequivalence of drug racemates: what are the cues from a bioanalytical perspective-stereoselective vs nonstereoselective?
    Srinivas NR
    Biomed Chromatogr; 2008 Nov; 22(11):1318-20. PubMed ID: 18651595
    [No Abstract]   [Full Text] [Related]  

  • 40. Tests for equivalence or non-inferiority--why?
    Drug Ther Bull; 2008 Jul; 46(7):55-6. PubMed ID: 18603641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.